-+ 0.00%
-+ 0.00%
-+ 0.00%

Citizens Maintains Market Outperform on Nasus Pharma, Lowers Price Target to $18

Benzinga·03/26/2026 13:05:37
Listen to the news
Citizens analyst Jason N. Butler maintains Nasus Pharma (AMEX:NSRX) with a Market Outperform and lowers the price target from $19 to $18.